OncoSec Medical Inc., a California-based developer of immunotherapies, announced it has appointed Sara M. Bonstein its new chief financial officer and chief operating officer.
Bonstein will be in charge of the company’s financial and capital market activities as well as its G&A functions and technical operations.
“Sara is a seasoned strategic executive with significant experience in the public biotechnology and pharmaceutical industry,” said Daniel J. O’Connor, CEO and president of OncoSec. “She joins OncoSec at an extremely important time, as we look to achieve several key milestones in the remainder of 2018. Sara has a proven track record of success and I am pleased she chose to join OncoSec.”
Prior to OncoSec, Bonstein was at Advaxis as its chief financial officer, secretary, treasurer and executive vice president. Before that, she held leadership roles in Eli Lilly & Company, ImClone Systems and Johnson & Johnson.
She holds a B.S. in finance from The College of New Jersey and an MBA from Rider University.
Bonstein will succeed Richard Slansky, CFO, who is leaving the company to pursue new opportunities.
“We would like to thank Richard for his hard work and dedicated service to OncoSec and we wish him well in his new endeavors,” O’Connor said.
